Sarepta Therapeutics Announces U.S. FDA Acceptance of an Efficacy Supplement to Expand the ELEVIDYS IndicationBusiness Wire • 02/16/24
1 of Sarepta Therapeutics' Competitors Just Got Hammered. Will It Help the Stock?The Motley Fool • 02/11/24
Sarepta Therapeutics Announces Positive Data from Part B of MOMENTUM, a Phase 2 Study of SRP-5051 in Patients with Duchenne Muscular Dystrophy Amenable to Skipping Exon 51Business Wire • 01/29/24
Sarepta Therapeutics: Leading The Way In DMD Treatment With Gene Therapy InnovationsSeeking Alpha • 01/24/24
Wall Street Analysts Think Sarepta Therapeutics (SRPT) Could Surge 29.51%: Read This Before Placing a BetZacks Investment Research • 01/22/24
Catalyst Countdown: 3 Biotech Stocks With Upcoming News That Could Move the MarketInvestorPlace • 01/16/24
Sarepta Therapeutics Initiates Screening in EMERGENE, a Phase 3 Clinical Study of SRP-9003 for the Treatment of Limb-Girdle Muscular Dystrophy Type 2E/R4Business Wire • 01/16/24
Sarepta Therapeutics (SRPT) Surges 16.7%: Is This an Indication of Further Gains?Zacks Investment Research • 01/10/24